Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan

Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan

Background Deucravacitinib is a selective oral tyrosine kinase 2 (TYK2) inhibitor recently approved for psoriasis.Objectives We aimed to evaluate the real-world effectiveness and safety of deucravacitinib for psoriasis.Methods We analyzed 33 Japanese patients with psoriasis (23 with plaque psoriasis...

Full description

Bibliographic Details
Main Authors:	Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	Journal of Dermatological Treatment
Subjects:	Psoriasis deucravacitinib tyrosine kinase 2 Japanese pruritus real-world clinical practice
Online Access:	https://www.tandfonline.com/doi/10.1080/09546634.2024.2307489

Similar Items

Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial
by: Ian M. Catlett, et al.
Published: (2024-09-01)

Deucravacitinib in the treatment of psoriasis
by: Tomás Estevinho, et al.
Published: (2023-12-01)

Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far
by: Ana Martins, et al.
Published: (2023-05-01)

Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects
by: Shan Jing, et al.
Published: (2023-11-01)

Exploring the effect of deucravacitinib in patients with palmoplantar pustular psoriasis
by: David A. De Luca, et al.
Published: (2024-12-01)

Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis
by: Jin JQ, et al.
Published: (2023-05-01)

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
by: April W. Armstrong, et al.
Published: (2023-07-01)

Treatment of oral lichen planus using deucravacitinib
by: Mindy Vu, BS, et al.
Published: (2024-02-01)

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
by: Potestio L, et al.
Published: (2023-05-01)

Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
by: Teppei Hagino, et al.
Published: (2024-12-01)

Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
by: April W. Armstrong, et al.
Published: (2024-10-01)

Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study
by: Teppei Hagino, et al.
Published: (2024-04-01)

Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials
by: Joseph F. Merola, et al.
Published: (2025-02-01)

Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
by: Neil J. Korman, et al.
Published: (2024-12-01)

Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis
by: April W. Armstrong, et al.
Published: (2024-06-01)

The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials
by: Jingyue Qiu, et al.
Published: (2023-09-01)

Fast and Sensitive Bioanalytical Method for the Determination of Deucravacitinib in Human Plasma Using HPLC-MS/MS: Application and Greenness Evaluation
by: Pottabattula Mahesh, et al.
Published: (2023-07-01)

Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis
by: April W. Armstrong, et al.
Published: (2023-10-01)

Dual‐Action Psoriasis Therapy: Antiproliferative and Immunomodulatory Effects via Self‐Locking Microneedles
by: Zi Yi Wang, et al.
Published: (2024-12-01)

Successful treatment of psoriasis vulgaris with ixekizumab in a patient with concurrent Sjögren’s syndrome presenting with dry eye and incomplete SLE
by: Marina Onda, et al.
Published: (2024-10-01)

Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan
by: Teppei Hagino, et al.
Published: (2023-12-01)

The differential effects of upadacitinib treatment on skin rashes of four anatomical sites in patients with atopic dermatitis
by: Teppei Hagino, et al.
Published: (2023-12-01)

A Scoping Review on Use of Drugs Targeting the JAK/STAT Pathway in Psoriasis
by: Francisco Gómez-García, et al.
Published: (2022-02-01)

Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways
by: Brandon Johnson, et al.
Published: (2024-09-01)

Pityriasis rosea-like drug eruption secondary to deucravacitinib
by: Nisal Punchihewa, MD, et al.
Published: (2024-11-01)

Treatment of hypertrophic lichen planus using deucravacitinib
by: Siddhartha Sood, HBSc, et al.
Published: (2024-09-01)

Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks
by: Teppei Hagino, et al.
Published: (2024-04-01)

Discoid lupus erythematosus successfully treated with deucravacitinib
by: Nnenna Ezeh, MD, et al.
Published: (2024-07-01)

The relationship between pruritus and clinical variables in patients with psoriasis
by: Anil Gulsel Bahali, et al.
Published: (2017-08-01)

Psoriasis and alcohol
by: Svanström C, et al.
Published: (2019-08-01)

Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis
by: Teppei Hagino, et al.
Published: (2024-12-01)

Early itch relief with upadacitinib predicts later skin clearance in Atopic dermatitis
by: Teppei Hagino, et al.
Published: (2024-12-01)

Real‐life self‐assessment of pruritus relief with a combination of calcipotriol/betamethasone dipropionate foam in patients with plaque psoriasis
by: Laurent Misery, et al.
Published: (2022-12-01)

Perianal Psoriasis as the First Manifestation of the Disease
by: Claudia Alejandra Aceves Quintero, et al.
Published: (2022-12-01)

Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States
by: Jashin J. Wu, et al.
Published: (2023-12-01)

Real-world efficacy and safety of apremilast monotherapy in the management of moderate-to-severe Psoriasis
by: Bela J Shah, et al.
Published: (2020-01-01)

Predicting Factors and Clinical Characteristics of Pruritus in Psoriasis: A Cross-Sectional Survey
by: Silviu-Horia Morariu, et al.
Published: (2024-06-01)

Density of mast cells and intensity of pruritus in psoriasis vulgaris: a cross sectional study
by: Letícia Pargendler Peres, et al.
Published: (2018-06-01)

The efficacy and safety of deucravacitinib compared to methotrexate, in patients with vulvar lichen planus who have failed topical therapy with potent corticosteroids: a study protocol for a single-centre double-blinded randomised controlled trial
by: Marlene Wijaya, et al.
Published: (2024-03-01)

Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study
by: Andreas Pinter, et al.
Published: (2024-05-01)